Tesla
TSLA
NVIDIA
NVDA
Advanced Micro Devices
AMD
Taiwan Semiconductor
TSM
Qualcomm
QCOM
US Stock MarketDetailed Quotes
REPL Replimune
- 12.620
- +0.060+0.48%
Close Jan 3 16:00 ET
- 12.620
- 0.0000.00%
Post 16:38 ET
950.80MMarket Cap-4.15P/E (TTM)
12.810High12.360Low528.73KVolume12.690Open12.560Pre Close6.65MTurnover1.05%Turnover RatioLossP/E (Static)75.34MShares17.00052wk High2.55P/B637.52MFloat Cap4.92052wk Low--Dividend TTM50.52MShs Float54.850Historical High--Div YieldTTM3.58%Amplitude4.920Historical Low12.584Avg Price1Lot Size
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Replimune Stock Forum
The market overall advanced Friday. Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ traded +0.35%, the $Dow Jones Industrial Average (.DJI.US)$ climbed 0.97%, and the $Nasdaq Composite Index (.IXIC.US)$ climbed 0.16%.
MACRO
In macroeconomics, S&P Global released its composite and service PMI. Composite came in at a two-year high, 55.3...
$Super Micro Computer (SMCI.US)$ climbed 15%, after earlier this week, the firm said it submitted a plan to release its six-month delayed 10k with a new auditor, BDO USA, and filed for a time extension to file it...
Replimune Receives Breakthrough Therapy Designation for Rp1 and Submits Rp1 Biologics License Application to the FDA Under the Accelerated Approval Pathway
No comment yet